Topic:

Financials

Latest Headlines

Latest Headlines

The massive med tech IPO: ConforMIS, Glaukos and Natera aim for $100M+

Custom knee implant maker ConforMIS has priced the latest major med tech IPO with its $135 million offering on July 1. Investor appetite for large med tech IPOs raising more than $100 million remains whetted, despite the encroachment of the summer doldrums that can slow Wall Street activity to a crawl.

India's Marksans Pharma Buys U.S.-based Time-Cap, a trend in the making?

More than a few analysts and company executives are watching Indian drug companies in expectations of consolidation among smaller players and possibly daring moves by mid-cap and larger at home and abroad.

Investors punish micro-cap EnteroMedics as it raises $35M to market recently approved obesity device

Wall Street remains skeptical of the first obesity device to be approved by the FDA in more than a decade. The agency approved VBLOC Vagal Blocking Therapy via the EnteroMedics Maestro System in January based on less-than-stellar pivotal data and a mixed panel review. Some investors are backing the company in its follow-on, which has raised $35 million, but at very steep terms.

No artful tax dodging here, drug firms tell Australia transfer-price inquiry

We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.

Aratana shares soar on positive trial of appetite stimulator for dogs

Late in the day on Friday, Kansas City animal health company Aratana Therapeutics announced successful results of a pivotal trial of capromorelin (AT-002), which stimulates appetite in dogs. The company's shares skyrocketed 25% to $16.74 in after-hours trading.

Blurred lines in Japan's vision for healthcare in next two decades

Japan's efforts to blend cost savings and innovation are so tied up in broader national goals to revive the deflation-hit economy that a plan had to be drawn up for the next two decades--but the documents and slides to describe the ideas seem to deftly avoid any look at the hard choices needed.

Sanofi's Brandicourt faces skeptical unions, anxious shareholders

One of the episodes that got ex-Sanofi CEO Chris Viehbacher fired was his very public run-in with France's unions when he decided jobs cuts were needed in France to trim costs. Now we will see if his successor can fare any better as Olivier Brandicourt tries to cut costs and build revenue for a company that faces challenges.

India's Zenotech committee says Sun Pharma stake offer 'fair and reasonable'

An INR202.3 million ($3.2 million) offer for a 28% stake in India's Zenotech Laboratories by Sun Pharmaceutical Industries is "fair and reasonable," according to a special committee named by the target company to evaluate the proposed transaction.

Australia's Ley hits back at drug firms on access to new medicines, reimbursement policies

A growing tussle between industry and Australia's Liberal-led coalition over efforts to trim drug reimbursement costs widened this week as Health Minister Sussan Ley hit back at Medicines Australia over the approval times for newer treatments and related costs.

Sebacia raises $22M to get gold microparticle acne treatment through FDA, launch

Georgia-based startup Sebacia hopes to gain FDA approval for the first physician office treatment to offer acne patients relief. It has raised $22 million to complete its U.S. pivotal trial, submit to the FDA and even start its U.S. launch.